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Abstract
Background and aims
Increased levels of chemokine interferon-gamma (IFN-γ)-inducible protein-10 (CXCL10),
soluble CD163 (sCD163) and soluble CD14 (sCD14) have been reported in HCV infection.
The aim of this study was to compare, sCD163 and sCD14 levels in HCV-infected patients
undergoing direct acting antiviral (DAA)-containing regimens with or without interferon
(IFN).
Methods
sCD163, sCD14 and CXCL10 were longitudinally measured by ELISA in 159 plasma sam-
ples from 25 HCV-infected patients undergoing IFN-based treatment plus telaprevir or
boceprevir and 28 HCV infected subjects treated with DAA IFN-free regimens. Twenty-five
healthy donors (HD) were included as controls.
Results
At baseline CXCL10, sCD163 and sCD14 levels were higher in HCV-infected patients than
in HD. CXCL10 and sCD163 levels were significantly decreased in responder (R) patients
who achieved sustained virological response (SVR), with both IFN-based and IFN-free regi-
mens, while they were persistently elevated in non-responders (NR) patients who stopped
IFN-based treatments because of failure or adverse events. Conversely, sCD14 levels
were apparently unchanged during therapy, but at the end of treatment the levels reached
normal ranges. Comparing the two regimens, the extent of CXCL10 reduction was more
pronounced in patients undergoing DAA IFN-free therapies, whereas sCD163 and sCD14
reduction was similar in the two groups.
Interestingly, only in IFN-based regimens baseline sCD163 levels were significantly
higher in NR than in R patients, while in the IFN-free treatment group also patients with high
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sCD163 plasma levels obtained SVR. At the end of therapy, even if the biomarkers were
largely decreased, their levels remained significantly higher compared to HD. Only in the
early fibrosis stages, sCD163 values tended to normalize.
Conclusions
These results indicate that IFN-free regimens including newer DAA induce an early and
marked decrease in circulating inflammatory biomarkers. However, the full normalization of
biomarkers was not obtained, especially in patients with advanced fibrosis, thus underlying
the need for a treatment in the early stages of HCV infection.
Introduction
Hepatitis C virus (HCV) is a major cause of liver disease worldwide, leading to progressive
fibrosis, potential development of cirrhosis and hepatocellular carcinoma (HCC) [1]. For
years, the standard of care of HCV chronic infection has been the treatment with interferon
alpha (IFNα)-based regimens. The advances in therapy from the use of standard IFNα mono-
therapy to pegylated IFNα (PEG-IFNα) in combination with ribavirin (RBV) and, then,
to first generation protease inhibitors telaprevir (TVR) and boceprevir (BOC) resulted in
improvements in the rates of sustained virological response (SVR) [2]. Nevertheless, in the last
years, a remarkable success in the management of HCV infection was obtained with the intro-
duction in clinical practice of several all-oral IFN-free direct acting antiviral agents (DAAs).
These new drug classes improved SVR rate up to 95–100% of cases, increasing the possibility
of HCV clearance [3].
Since IFN-free DAA regimens have specific steps of the virus life cycle as a target, they help
clarifying the interaction between HCV and the innate immune response, regardless of the
IFNα induced immune modulation [4]. It is well known that sustained inflammation and
fibrinogenesis represent the basis of liver damage during chronic HCV infection [5]. This pro-
cess is associated with increased production of inflammatory chemokines and mediators [6]
and a permanent activation of the innate immune system, including natural killer (NK) cells
and liver monocytes/macrophages, mostly Kupffer cells [7,8]. Various inflammatory and
innate immune activation biomarkers have been studied during chronic HCV infection and
are correlated with liver disease progression, as well as with the development of HCV extrahe-
patic manifestations, such as cardio-cerebrovascular diseases [9–11]. The complex interactions
between these inflammatory biomarkers and the outcome of HCV infection have led to studies
on the effect of antiviral treatment for HCV. In the pre-DAAs IFN-based treatment era, the
analysis of circulating biomarkers improved the understanding of immune responses to HCV
infection and showed their usefulness in predicting therapeutic responses [12–14]. Among
plasma biomarkers, we studied chemokine interferon-γ-inducible protein-10 (CXCL10), solu-
ble (s) CD163 and sCD14, because they play an important role in the pathogenesis of HCV
infection and have been associated with hepatic inflammatory activity and fibrosis stage [15–
17]. Nowadays, the evaluation of the effect of newer IFN-free regimens on the temporal
dynamics of inflammatory biomarkers represents an area of active investigation.
In the present study, we evaluated the effects of DAA-containing regimens with or without
IFN in a cohort of HCV infected patients, on dynamic changes in circulating levels of the fol-
lowing biomarkers of innate inflammation and immune activation: i) CXCL10, an inflamma-
tory chemokine reflecting liver expression of interferon stimulated genes; ii) sCD163, a
Inflammatory biomarkers in HCV-infected patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0179400 June 21, 2017 2 / 14
10; HCV, hepatitis C virus; HD, healthy donors;
LSM, liver stiffness measure; NK, natural killer; NR,
Non Responders; PLT, platelets; R, Responders;
RBV, ribavirin; sCD14, soluble CD14; sCD163,
soluble CD163; SVR, sustained virological
response; TVR, telaprevir.
marker of monocyte/macrophage activation; iii) sCD14, a marker of immune activation and
microbial translocation.
Patients and methods
Study population
The study was conducted in two out-patient clinics of a single referral center (Sapienza Uni-
versity, Rome). The study population included 53 patients with active HCV infection who
were treated according to the current Italian national guidelines for HCV treatment. Patients
had no evidence of HIV or HBV infection or decompensated liver disease. Based on treatment
response, patients were classified as responders (R) if they reached sustained virological
response, defined as undetectable HCV RNA in blood 12 weeks after the end of therapy
(SVR12). The subjects who stopped treatment because of virological failure (NRvf) or side
effects (NRse) were defined as non responders (NR). Twenty-five healthy donors (48, 32–58
years; 42% male/female) were included as controls.
The study was approved by the Ethics Committee of “Sapienza” University of Rome. All
subjects signed a written informed consent before enrolment in the study. Data and plasma
samples were collected respecting donor’s confidentiality and privacy.
HCV-RNA and HCV genotype testing
Plasma HCV-RNA levels were determined by RealTime PCR Roche Cobas TaqMan. HCV
genotypes and subtypes 1a and 1b were determined by Abbott RealTime HCV Genotype II.
Liver fibrosis assessment
Liver stiffness (measured in kPa) was determined by transient elastography with the use of a
Fibroscan machine (Echosens). Advanced fibrosis (F4) was defined as a liver stiffness measure
(LSM) greater than or equal to 14.5 kPa, severe fibrosis (F3) was defined as a LSM greater than
or equal to 10, mild or no fibrosis (F0-F2) was defined as a LSM less than 10 kPa [18]. The bio-
chemical index FIB-4 was also used to assess liver fibrosis and calculated using Sterling’s for-
mula: age [years] × AST [IU/L]/platelet count [expressed as platelets × 109/L] × (ALT1/2 [IU/L]).
Samples handling
Venous blood samples were collected from each patient into EDTA and heparin containing
tubes (Becton–Dickinson Systems, San Jose, CA) and the cell-free plasma was stored at -80˚C
until use. A total of 159 plasma samples were collected from HCV-infected patients and 25
from healthy donors. The patients were scheduled for plasma collection using the following
timing: T0 = baseline before therapy; T1 = after 4 weeks of therapy; T2 = 12 weeks after the
end of treatment for R patient or the time of failure (stopping rule) for NR subjects.
Detection of soluble biomarkers
Commercially available ELISA kits were used for the quantitative detection of plasma levels of
CXCL10, sCD163 and sCD14 (Quantikine, R&D Systems, Minneapolis, MN), according to the
manufacturer’s instructions. To preserve the linearity of the assays, samples containing high
concentrations of CXCL10 or sCD163 and sCD14 were diluted with an appropriate amount
of calibrator diluent. The reported minimum detectable doses of CXCL10, sCD163 and
sCD14 were 1.67 pg/ml, 0.177 ng/ml and 0,125 ng/ml, respectively. All samples were tested in
duplicate.
Inflammatory biomarkers in HCV-infected patients
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Statistical analysis
All statistical analyses were performed using GraphPad Prism Software version 5 (Software
MacKiev). Values are given as median and ranges. Non-parametric Mann-Whitney test and
non-parametric Kruskal-Wallis ANOVA with Dunn’s post-test were applied to compare the
differences in values. Non-parametric Friedman test with Dunn’s multiple comparison test
was applied to perform longitudinal analyses. We assessed the correlations between inflamma-
tory and clinical parameters using Spearman’s correlation coefficient (r). All statistical analyses
were considered significant with p-values less than<0.05.
Results
Study population characteristics
The clinical characteristics of the 53 HCV-infected patients receiving anti-HCV therapy are
shown in Table 1. Twenty-five subjects were treated with an IFN-based treatment including
PEG-IFNα/RBV plus first generation protease inhibitors (TVR or BOC), whereas 28 subjects
were treated with IFN-free DAA regimens with or without RBV.
In the IFN-based treatment group, 13 patients (52%) were responders and 12 (48%) non-
responders, of which 33% NRvf and 67% NRse. All patients treated with IFN-free DAA regi-
mens were responders, since they reached SVR12.
Table 1. Study population characteristics.
Characteristics IFN-based IFN-free P
treatment group treatment group
(n = 25) (n = 28)
Age (Years) 49 (23–67) 61 (43–78) 0.0008
Male/Female; n (% male) 20/5 (80%) 25/3 (88%) NS
HCV-RNA level, copies x 106/mL (median,ranges) 2.28 (0.07–7.9) 0.8 (0.01–12.8) 0.0013
Genotypes (Treatment)
1a 8 (TVR = 3; BOC = 5) 7 (SOF+ SIM = 7) NA
1b 17 (TVR = 10; BOC = 7) 14 (SOF+ SIM = 6; SOF+LED = 3; 3D = 4; SOF+DAC = 1) NA
2 0 4 (SOF = 3; SOF+SIM = 1) NA
3 0 1 (SOF = 1) NA
4 0 2 (SOF+SIM = 2) NA
ALT level, IU/L (median,ranges) 105 (42–288) 97.5 (28–407) NS
AST level, IU/L (median,ranges) 73 (26–280) 84 (26–178) NS
PLT (109/L) (median,ranges) 170 (34–290) 138 (67–340) NS
Liver Stiffness (kPA) 11.6 (1.3–37.4) 21 (10.9–45.7) 0.0006
FIB-4 Index (median,ranges) 2.1 (0.5–20.4) 3.8 (1.5–11.5) 0.002
SVR-12; n (%) 13 (52%) 100% <0.0001
Non-responders; n (%) 12 (48%) 0 NA
Virologic failure 4 (33%)
Side effects 8 (67%)
Results are expressed in median (range). For continuous variable Mann-Whitney test and for variable dichotomous Chi-Square test were performed.
HCV-RNA: hepatitis C virus ribonucleic acid, TVR: Telaprevir, BOC: Boceprevir, SOF: Sofosbuvir, SIM: Simeprevir, LED: Ledipasvir, 3D: Ombitasvir,
Paritaprevir, Dasabuvir, DAC: Daclatasvir, ALT: alanine aminotransferase, AST: aspartate aminotransferase, PLT: platelets, SVR: sustained virologic
response, NA: not applicable, NS: not significant.
https://doi.org/10.1371/journal.pone.0179400.t001
Inflammatory biomarkers in HCV-infected patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0179400 June 21, 2017 4 / 14
Soluble biomarkers plasma levels in treatment groups and healthy
controls
Plasma levels (median, ranges) of CXCL10 (412.8, 133.8–568.5), sCD163 (1572.6, 790.6–
4119.7) and sCD14 (1732.1, 1007.5–3310) in HCV-infected patients at baseline were signifi-
cantly higher than in HD (81.3, 27.7–236.3; 457.6, 279.2–810.5; 1341.4, 917.4–2627.4, respec-
tively) (Fig 1, Panel A).
When we analyzed the levels of biomarkers according to fibrosis stage at baseline, all groups
showed higher levels of CXCL10 and sCD163 in comparison with HD (p<0.001), while
sCD14 levels were similar in subjects with F0-F2, F3 liver fibrosis and HD (p>0.05), and were
increased only in cirrhotic subjects (p = 0.03) (Fig 1, Panel B).
Patients with severe fibrosis (F4) had significantly higher sCD163 concentrations
(1785.7,1169.5–4119.7) compared to those with mild fibrosis (F0-F2) (1194, 790.6–2201.7)
(p = 0.001), while no statistically significant differences for CXCL10 and sCD14 levels were
found. Moreover, CXCL10 levels positively correlated with FIB-4 (r = 0.4; p = 0.003); sCD163
levels positively correlated with FIB-4 (r = 0.5; p = 0.0004), hepatic stiffness (r = 0.5; p = 0.001),
AST (r = 0.4; p = 0.008) and negatively with viremia (r = -0.3; p = 0.03) and platelet absolute
counts (r = -0.3; p = 0.02).
Longitudinal changes in soluble biomarkers during treatment
CXCL10 levels. Changes in the levels of CXCL10 in IFN-based treatment group (R and
NR) and IFN-free DAA regimens are shown in Fig 2. At baseline in the IFN-based treatment
Fig 1. Plasma levels of CXCL10, sCD163 and sCD14 in HCV-infected patients and healthy controls.
Panel A: Box plots represent circulating levels of CXCL10 (n = 53), sCD163 (n = 53) and sCD14 (n = 45) in
HCV-infected patients at baseline and in 25 HD. Statistical differences were assessed by Mann-Whitney and
p are indicated. Panel B: Box plot represents circulating levels of CXCL10, sCD163 and sCD14 in HCV-
infected patients according to fibrosis stage at baseline. Horizontal bars represent the median values and
dashed lines indicate the median value of HD. Kruskal-Wallis ANOVA with Dunn’s test were performed to
assess statistical differences between the different groups. HCV: hepatitis C virus; HD: healthy donors;
F2-F0: absent to mild liver fibrosis; F3: severe liver fibrosis; F4: advanced liver fibrosis; NS: not significant.
https://doi.org/10.1371/journal.pone.0179400.g001
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group, there was not a significant difference in CXCL10 levels between NR (n = 12) and R
subjects (n = 13) (p = 0.18). The median (ranges) CXCL10 levels were 426.9 (142.3–568.5) in
NR patients and 307.2 (159.9–495.4) in R patients. A significant decrease in CXCL10 concen-
trations was found one month after initiation of therapy only in R patients and its values
remained low up to the SVR12 (T2) (p = 0.004). The median (ranges) value of CXCL10 at base-
line was 307.2 (159.9–495.4) and decreased to 249.41 (108.5–495.4) at T1 and 162.4 (115.2–
457.8) at T2 (p = 0.004 for T2 versus T0). Conversely, in NR patients, after an initial significant
decrease at T1, CXCL10 levels increased at the time of stopping rule. The median (ranges)
CXCL10 levels in NR patients were 426.9 (142.3–568.5) at T0, 229.8 (90.1–291.6) at T1 and
345 (164.3–1154.1) at the time of stopping rule (p = 0.02 for T1 versus T0).
In the group of patients treated with IFN-free DAA regimens, there was a marked decrease
of CXCL10 plasma levels at T1 and its values remained low up to SVR12 (T2) (p<0.0001). The
median (ranges) CXCL10 levels were the following: 451.8 (133.8–568.5) at T0, 123.2 (81.5–
568.5) at T1, 137.4 (36–517.6) at T2 (p<0.0001 for both T1 and T2 versus T0).
sCD163 levels. The basal sCD163 levels in the IFN-based treatment group were signifi-
cantly higher in NR patients (median 1702.8, ranges 1139.8–2201.7) than in R patients (1208.1,
790.6–1570.2) (p = 0.0005). During the IFN-based treatment, sCD163 levels significantly
decreased in R patients only at T2 (SVR12) (p<0.0001). The median (ranges) sCD163 levels
were 1208.1 (790.6–1570.2) at T0, 1062.6 (755.1–1372.1) at T1 and decreased to 635.6 (462.3–
1332.1) at T2 (p<0.0001 T2 vs T0). Conversely, in NR patients, after an initial significant
decrease at T1, sCD163 levels increased at the time of stopping rule. The median (ranges)
Fig 2. Longitudinal changes in soluble biomarkers in HCV-infected patients undergoing DAA
containing regimen with or without IFN. Box plots represent circulating levels of CXCL10 (n = 53), sCD163
(n = 53) and sCD14 (n = 45) in HCV-infected patients at T0, T1 and T2 in R patients during IFN-based
treatment, at T0, T1 and T2 in NR patients during IFN-based treatment and at T0, T1 and T2 during IFN-free
treatment. Box plots show 10th, 50th (median), 90th, percentile and whiskers. Horizontal bars represent the
median values. Statistical analysis was performed using Friedman test, p values indicate the no post-test. R:
responders; NR: non responders; T0: baseline before therapy; T1: after 4 weeks of therapy; T2: 12 weeks
after the end of treatment for R patient or the time of failure (stopping rule) for NR subjects.
https://doi.org/10.1371/journal.pone.0179400.g002
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sCD163 levels in NR patients were 1702.8 (1139.8–2201.7) at T0, 1178.1 (1098.5–1591.4) at T1,
1546.5 (717.8–2201.7) at the time of stopping rule (p = 0.02 for T1 versus T0) (Fig 2).
In patients treated with IFN-free DAA regimens, sCD163 levels decreased after one month
of therapy and its values remained low up to SVR12 (T2) with only a moderate increase (p =
0.0004). The median (ranges) sCD163 levels were the following: 1905 (1124.1–4119.7) at T0,
1161.7 (617.2–3044) at T1, 1524.1 (563.2–4002.3) at T2 (p = 0.0004 for T1 versus T0) (Fig 2).
sCD14 levels. Unlike sCD163, there was not a significant difference in sCD14 levels
between NR and R subjects at baseline in the IFN-based treatment group (p = 0.76). The
median (ranges) sCD14 levels in NR patients were 1602.5 (1007.5–3310) and 1547.5 (1082.5–
3305) in R patients.
During the IFN-based treatment, sCD14 levels slightly decreased without statistically signif-
icant differences in both R and NR patients. The median (ranges) sCD14 levels were the fol-
lowing in R: 1547.5 (1082.5–3305) at T0, 1335 (956–1677.5) at T1, 1132.5 (842.5–2085) at T2
(p>0.05). The median (ranges) sCD14 levels in NR were the following: 1602.5 (1007.5–3310)
at T0, 1214.25 (832.5–1852.5) at T1, 1246 (832.5–2612.5) at T2 (p>0.05). Also in patients
receiving IFN-free DAA regimens, there was no significant decrease in sCD14 levels. The
median (ranges) sCD14 levels were the following: 1778.9 (1092.5–2612.5) at T0, 1587.8 (552.5–
2940) at T1, 1613.3 (1484.3–2347.5) at T2 (p>0.05) (Fig 2).
Different impact of anti-HCV regimens on soluble biomarkers
In order to assess if IFN-based triple regimen or IFN-free DAA therapy exhibit a different
effect on CXCL10, sCD163 and sCD14 levels, we calculated for each biomarker the reduction
rate at T1 and T2 versus baseline (Fig 3A–3C). We observed a significant greater reduction
rate for CXCL10 during IFN-free therapies, in comparison to IFN-based treatments. CXCL10
reduction rate at T1 and T2 was 60% vs 14% and 66% vs 31%, respectively (Fig 3A); for
sCD163 it was 18% vs 11% and 16% vs 27%, respectively (Fig 3B); for sCD14 23% vs 7% and
1% vs 29%, respectively (Fig 3C).
Biomarkers normalization in HCV-infected patients with sustained
virological response
To assess the degree of normalization of the three biomarkers at SVR12, we compared the lev-
els of CXCL10, sCD163 and sCD14 at T2 (SVR12) with controls HD. Despite a decrease in
Fig 3. Different impact of anti-HCV regimens on soluble biomarkers. Box plots represent the reduction rate of CXCL10
(panel A), sCD163 (panel B) and sCD14 (panel C) at T1 and T2 versus T0. Box plots show 10th, 50th (median), 90th, percentile
and whiskers. Horizontal bars represent the median values. Statistical differences were assessed between IFN-based versus
IFN-free treatment group at T1 and T2, by Mann-Whitney test. T0: baseline before therapy; T1: after 4 weeks of therapy; T2:
12 weeks after the end of treatment for R patient.
https://doi.org/10.1371/journal.pone.0179400.g003
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concentrations, CXCL10 and sCD163 levels did not reach normal values and remained signifi-
cantly higher than in HD (p = 0.001 for CXCL10 and p<0.0001 for sCD163) (Fig 4A and 4B).
On the other hand, sCD14 levels at SVR12 were comparable with those of HD (p>0.05) (Fig
4C).
Interestingly, after stratifying patients according to fibrosis stage, CXCL10 levels remained
significantly higher, also in patients with low fibrosis, compared to HD (Fig 4D). Conversely,
sCD163 levels decreased in patients with low fibrosis reaching values comparable to those
observed in HD (Fig 4E), even if the baseline sCD163 levels were extremely higher than those
measured in controls (1194, 790.6–2201.7 and 457.6, 279.2–810.5, p<0.0001). Regarding
sCD14, plasma levels remained significantly higher only in cirrhotic patients (Fig 4F), who
showed elevated levels also at baseline. Moreover, subjects with F0-F2 and F3 fibrosis, who
showed only a moderate increase of sCD14 at baseline, had normal levels in comparison with
HD at SVR12.
Discussion
In this study, we analyzed the temporal modifications of biomarkers of inflammation and
immune activation in a cohort of HCV-infected patients undergoing DAA therapies using
both IFN-based and IFN-free regimens. The circulating levels of CXCL10, sCD163 and sCD14
were assessed at baseline and during the course of treatment and results were analyzed in
terms of virological outcome and response to therapy. As previously reported [19], we found
higher plasma concentrations of the three biomarkers at baseline in comparison to controls
Fig 4. CXCL10, sCD163 and sCD14 normalization in HCV-infected patients with sustained virological
response. CXCL10 (panel A), sCD163 (panel B) and sCD14 (panel C) in HCV-infected patients at T0, T2 and
in HD. CXCL10 (panel D), sCD163 (panel E) and sCD14 (panel F) in treated HCV-infected patients according
to liver fibrosis degree at T2 and in HD. Horizontal bars represent the median values and horizontal dashed
line in panel D, E and F indicates the median values of HD. Kruskal-Wallis ANOVA with Dunn’s test were
performed to assess statistical differences between the different groups. T0: baseline before therapy; T2: 12
weeks after the end of treatment for R patient; F2-F0: mild to absence of fibrosis; F3: severe fibrosis; F4:
advanced fibrosis; HD: healthy donors; NS: not significant.
https://doi.org/10.1371/journal.pone.0179400.g004
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suggesting systemic immune activation and inflammation, even in the low fibrosis stages of
HCV-related disease.
CXCL10 is a member of the CXC subfamily of chemokines induced in monocytes, fibro-
blasts, and endothelial cells by IFN-γ [4]. After binding to its receptor CXCR3, CXCL10 acts as
a chemoattractant for CXCR3+ cells such T lymphocytes, monocytes and NK cells. Intrahepa-
tic and peripheral levels of CXCL10 are elevated in HCV-infected patients with high levels of
liver inflammation and fibrosis [20]. The expression of CXCL10 mRNA by hepatocytes corre-
lates with serum CXCL10 levels [21] suggesting that CXCL10 may be a valid surrogate marker
of innate immune response activation and of ISG activation in the liver [22]. During HCV
infection, T-helper 1 (Th1) lymphocytes secrete cytokines, such as IFN-γ and IL-2, which acti-
vate monocytes and macrophages [23]. This immune reaction leads to liver tissue damage and
consequent progressive liver disease [24]. In the present study, CXCL10 levels significantly
decreased in patients reaching SVR12, suggesting that the decline of this chemokine could be
an indicator of disruption of the intrahepatic virus-host interaction. Our study is in accor-
dance with Romero A.I. et al. 2006, who showed a reduction in responders after 6 weeks of
IFN/RBV therapy [13]. Indeed, we found a decrease of CXCL10 levels in SVR patients after
only one month of therapy, concurrently with HCV suppression. On the other hand, the
increased production of CXCL10 in NR patients who stopped treatment for failure or adverse
effects may be driven by the rebound of viral replication.
In a recent study, successful treatment with daclatasvir and asunaprevir decreased serum
levels of the ISG products CXCL10 and CXCL11, together with a decrease in STAT1 expres-
sion and STAT1 phosphorylation in NK cells [25]. In our R patients, we also compared the dif-
ferent impact of the IFN-based and IFN-free regimens on the degree of CXCL10 reduction.
Although in R patients the two regimens were both effective in terms of control of HCV repli-
cation, a significantly greater reduction of CXCL10 levels was found in the IFN-free than in
the IFN-based treatment group. Nevertheless, despite the significant reduction in CXCL10
during treatment, the levels did not reach normal values, suggesting the persistence of residual
inflammation. In our study population, we could not observe a significant difference in
CXCL10 levels between patients with advanced fibrosis and in those with mild fibrosis, as
reported by Diago M. et al. [26], thus underlying the presence of immune activation even in
the low fibrosis stages. However, in accordance with Romero A.I. et al [13], we found a positive
correlation between CXCL10 levels and fibrosis index (FIB-4), suggesting a possible role of
CXCL10 as a non-invasive marker of liver fibrosis.
Furthermore, we studied two markers of monocyte activation, sCD163 and sCD14, which
contribute to hepatic inflammation and fibrosis. sCD163 is an important marker of macro-
phage activation, involved in the activation of hepatic stellate cells during the progression of
chronic liver disease [27,28]. In our study, we found higher levels of sCD163 in HCV-infected
patients compared to HD, confirming that sCD163 plays an important role in the pathogenesis
of HCV infection [29]. In accordance with Kazankow K. et al. [16], we found higher levels
of sCD163 in patients with advanced fibrosis (F4) compared to patients with mild fibrosis
(F0-F2), showing that sCD163 could play a role in determining the severity of hepatitis. Fur-
thermore, in our study sCD163 levels correlated with fibrosis assessments (FIB-4 and stiffness),
suggesting that sCD163 is a promising fibrosis marker during HCV infection [30]. Moreover,
the increase in monocyte activation markers has been associated with several cardiovascular
and neurodegenerative diseases, such as subclinical carotid artery disease in general popula-
tion and in HCV or HIV infected subjects [31–34], suggesting a possible extra-hepatic effect of
HCV, mediated by monocyte activation.
During anti-HCV therapies, sCD163 levels significantly decreased in R patients undergoing
both IFN-based or IFN-free regimens, while they remained high in NR patients who stopped
Inflammatory biomarkers in HCV-infected patients
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IFN-based treatments for failure or adverse effects. Comparing the two treatment strategies,
even if the rate of reduction was lower at T1 in the IFN-based treatment group, no statistically
significant differences were observed between the two regimens. Furthermore, in patients
who were treated with IFN-based therapy, significantly higher baseline sCD163 levels were
observed in NR patients compared to R patients, while in the IFN-free group all patients
obtained SVR, including those with higher levels of sCD163 at baseline. Although all patients
were treated with DAAs, the response to first generation DAA protease inhibitors was still
dependent on the immunomodulating effect of INFα. Comparing inflammation markers
reduction rate, we observed a less marked decrease in sCD163 than in CXCL10 plasma levels.
Moreover, patients obtaining SVR12 still showed higher levels of sCD163 when compared to
healthy subjects. In a recent study sCD163 and Mac2BP levels didn’t normalize within 6
months from the start of interferon-free therapy [35]. Interestingly, in our study, only patients
with low fibrosis showed a normalization of sCD163 plasma levels. These findings underline
the need to start therapy for HCV infection in an early stage of fibrosis in order to block HCV-
induced inflammation. In fact, the persistence of a systemic inflammatory response could
be responsible of an increased risk of inflammatory-related organ diseases in HCV infected
subjects.
Finally, systemic inflammation associated with gut derived microbial products has been
described during HCV infection [17]. sCD14 is a glycosyl phosphatidyl inositol that is
expressed on monocytes, macrophages, polymorphonuclear leukocytes and dendritic cells
[36]. CD14 is a marker of microbial translocation and is secreted in a soluble form upon
monocyte activation. It was demonstrated that sCD14 could be detected at high levels in
patients with HCV infections [36] and recent studies suggested a relationship between micro-
bial translocation and progression of liver disease during HCV infection [17]. However, ele-
vated levels of sCD14 have also been observed in patients with non-alcoholic steatohepatitis
[37], and common variable immunodeficiency [38], suggesting other possible origins of
sCD14 in plasma, one of which may be the liver.
In our study population, we found a moderate increase in sCD14 with a significant increase
only in patients with F4 liver fibrosis stage, as described previously [17]. In prior work [39]
no significant changes were found in sCD14 levels in patients with HCV infection during
PEG-IFNα/RBV therapy, whereas a recent study showed an increase in innate immune activa-
tion, measured as sCD14 and IL-18 elevation [40]. In this study the authors showed that a
group of patients with low baseline levels of these factors, had a very high SVR rate during the
course of dual therapy.
We found that sCD14 levels remained apparently unchanged both in NR and R patients at
the end of therapy, despite the control of HCV viremia with no differences between the two
therapies. Indeed, when comparing patients who obtained SVR12 with HD, sCD14 levels were
similar, but after stratifying patients according to fibrosis stage, cirrhotic subjects showed per-
sistently higher levels of sCD14, indicating a lack of normalization after HCV eradication.
The main limitations of our research are the different clinical characteristics of the two ther-
apeutic groups in terms of liver fibrosis and HCV genotypes due to the distinct indications in
the national guidelines at the time of treatment. In fact, current Italian guidelines for HCV
treatment allow the use of new DAAs only in patients with advanced fibrosis (F3-F4). More-
over, the number of subjects with low liver fibrosis was limited, together with a short post-
treatment follow-up interval.
In conclusion, our results suggest that the systemic levels of inflammatory biomarkers in
HCV-infected subjects were globally reduced by anti-HCV therapy, with a more pronounced
effect produced by IFN-free regimens on CXCL10 levels. A possible explanation is that
CXCL10 declines simoultaneously with the level of viremia and the new and potent therapies
Inflammatory biomarkers in HCV-infected patients
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with DAAs induce a rapid decrease in HCV replication with a subsequent sudden reduction of
CXCL10 plasma levels. This chemokine is induced after RIG-I and TLR-3 activation by HCV
RNA, which acts as a PAMP. Furthermore CXCL10 belongs also to the IFN-stimulated gene
family [41]. Thus, CXCL10 levels are directly related to viral load, while the other inflamma-
tory markers studied in our work are secondary immune events. In fact, CXCL10 should be
considered more linked to viral induced inflammation, while sCD163 and sCD14 more related
to secondary immune events that lead to hepatic fibrosis. Moreover IFN-based therapy could
induce an immune activation due to the direct effect of IFN that counteracts the anti-inflam-
matory role linked to HCV suppression.
At the end of therapy, CXCL10 and sCD163 plasma levels remain significantly higher than
in HD. Probably the chronic exposure to viral antigens may cause exhaustion of the immune
system, resulting in a slow immunological recovery. The low degree of immune recovery could
also have important clinical implications that prompt a close monitoring of immune-mediated
organ disease associated to with HCV. A recent study suggests that after SVR, T-cell function
remains abnormal and hyporesponsive in most cases probably because of cell exhaustion [42].
Only in patients with low fibrosis a normalization of sCD163 was achieved, suggesting the
need for an early therapeutic approach during HCV infection. A longer follow-up could clarify
if inflammation will resolve over time or persist after HCV eradication.
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